◆ FUNDING DATA
- Round
- Series B
- Amount
- $11.3M
- Location
- Research Triangle Park, United States
- Priority score
- 50/100
- Confidence
- 70/100
Series B
Incyclix Bio.
Incyclix Bio is advancing INX-315, a potent and selective CDK2 inhibitor, for treating cancers such as ovarian, breast, and lung cancers, particularly those resistant to CDK4/6 inhibitors.